logo
Share SHARE
FONT-SIZE Plus   Neg

PharmAthene Says FDA Places SparVax RPA Anthrax Vaccine Program On Clinical Hold

PharmAthene Inc. (PIP) has received notification from the U.S. Food and Drug Administration or FDA that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the company would get a letter containing the details of the basis for the clinical hold within 30 days.

The company, during this period, would continue to provide the agency with analytical data from its recently produced GMP lot of material. The trial, which was expected to commence by the year end, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Following the sell-off seen in the previous session, stocks showed a strong move back to the upside during trading on Wednesday. The markets benefited from a positive reaction to the latest batch of economic news. Frontier Airlines has crashed its own website after offering $1 fares from select U.S. markets. In another sign that the jobs market is improving, the Federal Reserve's Beige Book has reported increased wage pressures in a number of districts around the U.S. "Several" of the 12 district banks "reported increasing wage pressures caused by labor market tightening," according to the Beige Book,...
comments powered by Disqus
Follow RTT